Last reviewed · How we verify
NCT04182451
Effect of Meso Wound Matrix in the Treatment of DFUs
NA trial testing Meso Wound Matrix in Diabetic Foot Ulcers (DFUs) in 30 participants. Completed in 1 March 2023.
17 May 2022
Quick facts
| Lead sponsor | SerenaGroup, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 5 December 2019 |
| Primary completion | 17 May 2022 |
| Estimated completion | 1 March 2023 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Meso Wound Matrix
Conditions studied
- Diabetic Foot Ulcers (DFUs) — all drugs for Diabetic Foot Ulcers (DFUs) →
Sponsor
SerenaGroup, Inc. — full company profile →
Who can join
18 and older, any sex, with Diabetic Foot Ulcers (DFUs). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective trial designed to evaluate the use of Meso Wound Matrix (DSM Biomedical, Exton, PA) in Wagner grade 1 and 2 DFUs.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chronic Diabetic Wounds and Their Treatment with Skin Substitutes.
Holl J, Kowalewski C, Zimek Z, Fiedor P, et al · · 2021 · cited 205× · PMID 33804192 · DOI 10.3390/cells10030655 -
Innovative Functional Biomaterials as Therapeutic Wound Dressings for Chronic Diabetic Foot Ulcers.
Da Silva J, Leal EC, Carvalho E, Silva EA. · · 2023 · cited 27× · PMID 37373045 · DOI 10.3390/ijms24129900 -
Immunomodulatory Mechanisms of Chronic Wound Healing: Translational and Clinical Relevance.
Riaz M, Iqbal MZ, Klar AS, Biedermann T. · · 2025 · cited 1× · PMID 41127507 · DOI 10.1002/mco2.70378
Verify or expand the search:
- PubMed search for NCT04182451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Foot Ulcers (DFUs)
Currently open trials in the same condition.
- NCT06939686 — Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing · NA · recruiting
- NCT06939673 — Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care · NA · recruiting
Other SerenaGroup, Inc. trials
Trials by the same sponsor.
- NCT05198544 — Clinical Trial Evaluating a Hyaluronic Acid Matrix in the Treatment of Chronic Non-healing Diabetic Foot Ulcers (DFUs) · NA · unknown
- NCT05107050 — Comparing a Synergistic Antimicrobial Cleanser and Gel to Normal Saline and an Amorphous Gel in Reducing Bioburden and P · NA · unknown
- NCT05033470 — A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers · NA · unknown
- NCT05076578 — A Prospective Clinical Study Evaluating the Harvesting of Micografts · NA · completed
- NCT04888624 — A Comparison Between Two Post-operative Dressings · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04182451 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SerenaGroup, Inc.
- Last refreshed: 26 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04182451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing